Defense Dept. Funds Ketamine Study For PTSD Treatment In 600 Service Members & Veterans
Portfolio Pulse from Lara Goldstein
The Department of Defense is funding a Phase 2 study to test Seelos Therapeutics' SLS-002, an intranasal racemic ketamine, on 600 service members and veterans for PTSD treatment. The study will assess safety, tolerability, and efficacy over a 12-week treatment period with a 30-day screening and four-week follow-up. Seelos has two IND applications with the FDA for SLS-002 for acute suicidal ideation and behavior in MDD and PTSD. The study, expected to start soon in Georgia, will be completed by 2026. PTSD incidence has risen among veterans, and ketamine shows promise as a rapid and effective treatment for depression, suicidality, and PTSD.
November 27, 2023 | 7:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Seelos Therapeutics' SLS-002 is being tested in a DOD-funded Phase 2 study for PTSD treatment in service members and veterans. The company has FDA IND applications for SLS-002 in MDD and PTSD, indicating progress in clinical trials.
The news of DOD funding for a study involving Seelos Therapeutics' SLS-002 is likely to be viewed positively by investors, as it demonstrates both the potential of the treatment and the company's progress in clinical trials. The involvement in a government-funded study could also lead to increased visibility and credibility for Seelos, potentially impacting the stock price positively in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100